Japanese firms turn to four-day week to improve work-life balance
Companies open to the arrangement are hoping staff will acquire new skills or develop a network of contacts through additional education or a second job.
U.S. in talks with Japan's Shionogi to buy new COVID-19 pill
Shionogi's treatment is in late-stage clinical trials and hasn’t yet been authorized, but in earlier studies, it reduced viral loads in patients within the first few days of use.
Shionogi to recommend pregnant women not use oral COVID drug
Shionogi has filed for conditional early approval to skip the final stage of clinical trials once a certain level of efficacy and safety has been confirmed.
Shionogi signs supply deal with Japanese government for COVID-19 pill
The government is considering buying a million doses of the drug, pending regulatory approval.
Japanese firms near domestic rollout of their COVID-19 vaccines
Several companies are expecting to introduce their shots in the coming fiscal year, a major step in Japan reducing its reliance on foreign vaccine manufacturers.
Shionogi says its COVID-19 shot is effective and safe
The positive data could mean Japan, which is racing to complete a booster drive in hopes of curbing future outbreaks, will soon have an indigenous jab.
Shionogi seeks approval for Japan’s first domestic COVID pill
Kishida has signaled that the central government will expedite the review process to pave the way for a swift approval if the drug's efficacy and safety are confirmed.
Shionogi and hospital to research development of nasal COVID-19 vaccine
The firm has also developed an oral COVID-19 vaccine and is expected to apply for approval as early as next week following clinical trials that showed its effectiveness.
The company could file for early approval of the drug as soon as next week, and it could deliver enough doses for 1 million people by the end of March.
The delay was due to the lack of enough participants for a clinical trial of the oral drug currently being developed by the pharmaceutical firm.
Tardy COVID-19 vaccine makers under fire for trials in developing nations
Vaccine developers at the testing phase now are seeking developing countries where vaccination rates remain low and the virus is still active.
Japanese drugmaker Shionogi considers developing vaccine for omicron variant
The company is currently conducting a final clinical trial of its COVID-19 vaccine, aiming to make it available in March.
